Browsing Tag
Merck
102 posts
Can Merck turn Ohtuvayre into a global COPD blockbuster? A look at pricing, access, and lifecycle strategy
Can Merck scale Ohtuvayre into a global COPD blockbuster? Explore its pricing strategy, global access plans, and lifecycle ambitions in this in-depth analysis.
Merck to acquire Verona Pharma for $10bn, securing Ohtuvayre COPD therapy
Verona Pharma stock jumps 20% as Merck announces $10B acquisition to boost its COPD pipeline with first-in-class therapy Ohtuvayre. Read full analysis.
NeoGenomics appoints Merck oncology executive Dr. Marjorie Green to its board to advance leadership in precision diagnostics
NeoGenomics adds Merck oncology leader Dr. Marjorie Green to board, strengthening its precision diagnostics strategy and global pharmaceutical partnerships.
The oral biologics revolution: How macrocyclic peptides could reshape drug delivery
Macrocyclic peptides are revolutionizing oral biologics. Explore how Merck, Protagonist, and others are turning injectables into convenient, high-impact pills.
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.
Can Merck rebuild its cardiovascular empire post-Keytruda? A closer look at its next decade of drug growth
With Keytruda’s patent expiry nearing, Merck is betting on enlicitide and sotatercept to build a new cardiovascular empire. Can it succeed?
Merck advances pimicotinib in China as Center for Drug Evaluation accepts TGCT marketing application following pivotal Phase 3 data
Merck’s TGCT treatment pimicotinib moves closer to approval in China after CDE accepts marketing application; global filings planned next.
Merck (NASDAQ: MRK) wins FDA approval for ENFLONSIA to prevent RSV in infants
FDA clears Merck’s ENFLONSIA (NASDAQ: MRK) for RSV prevention in infants. See trial data, stock reaction, pediatric market impact & analyst projections.
Merck’s enlicitide shows major LDL-C reduction in Phase 3 trials, raising hopes for first oral PCSK9 approval
Merck’s enlicitide hits key milestones in Phase 3 trials, bringing the first oral PCSK9 inhibitor closer to market. Will this reshape LDL-C treatment?
Merus N.V. stock soars on breakthrough cancer trial: What drove MRUS to the top gainers list?
Merus N.V. stock jumped 32% on breakthrough cancer trial data. Find out what’s driving MRUS and what could come next for this biotech leader.